Hubungan Usia dengan Kadar Prostate Specific Antigen pada Penderita Benign Prostatic Hyperplasia di Laboratorium Patologi Anatomi RSUD Abdul Wahab Sjahranie Samarinda
DOI:
https://doi.org/10.25026/jsk.v2i4.224Abstract
Abstract
Benign Prostatic Hyperplasia (BPH) is a disorder of stromal cell hyperplasia and prostatic gland epithelial cells which is still a disease in the field of urology with the second highest morbidity rate in Indonesia. Many factors affect the occurrence of BPH, one of them is PSA level. The higher the PSA level, the faster the prostate growth rate. PSA levels increase with age. The purpose of this study was to determine the relationship of age with PSA levels. This study was an observational analytic study with a cross-sectional approach. Data regarding age variables and PSA levels of patients were taken from medical records. The results showed the average age of patients was 63.62 years and the average PSA level of patients was 12.65 ng / ml. There was a significant relationship between age and PSA levels (p=0.049).
Keywords : Age, Prostate Specific Antigen Levels, Benign Prostatic Hyperplasia
Abstrak
Benign Prostatic Hyperplasia (BPH) merupakan kelainan hiperplasia sel stroma dan sel epitel kelenjar prostat yang masih menjadi penyakit di bidang urologi dengan angka kesakitan tertinggi kedua di Indonesia. Banyak faktor yang mempengaruhi terjadinya BPH salah satunya adalah kadar PSA. Semakin tinggi kadar PSA maka semakin cepat laju pertumbuhan prostat. Kadar PSA meningkat sebanding dengan pertambahan usia. Tujuan penelitian ini adalah untuk mengetahui hubungan usia pasien dengan kadar PSA. Penelitian ini merupakan penelitian analitik observasional dengan pendekatan cross-sectional. Data mengenai variabel usia dan kadar PSA pasien diambil dari rekam medis. Hasil penelitian menunjukkan rata-rata usia pasien adalah 63,62 tahun dan rata-rata kadar PSA pasien didapatkan 12,65 ng/ml. Terdapat hubungan bermakna antara usia dan kadar PSA (p=0,049).
Kata Kunci: usia, kadar Prostate Specific Antigen, Benign Prostatic Hyperplasia
References
[2] K. T. McVary et al., “Management of Benign Prostatic Hyperplasia (BPH) Guideline,” AUA Clin. Guidel., 2016.
[3] B. B. Purnomo, “Dasar-dasar urologi,” Jakarta Sagung Seto, pp. 6–9, 2011.
[4] E. D. Yeboah, “Prevalence of Benign Prostatic Hyperplasia and Prostate Cancer in Africans and Africans in the Diaspora.,” J. West African Coll. Surg., vol. 6, no. 4, pp. 1–30, 2016.
[5] W. Wang, Y. Guo, D. Zhang, Y. Tian, and X. Zhang, “The prevalence of benign prostatic hyperplasia in mainland China: Evidence from epidemiological surveys,” Sci. Rep., vol. 5, no. August, pp. 1–12, 2015, doi: 10.1038/srep13546.
[6] D. M. Krisna, A. Maulana, and E. Kresnoadi, “Correlation between Prostate-Specific-Antigen ( PSA ) Level and Prostate Volume in Benign Prostatic Hyperplasia at Bhayangkara Hospital Mataram Daniel M Krisna *, Akhada Maulana **, Erwin Kresnoadi *** * Faculty of Medicine Duta Wacana Christian Universit,” Med. Heal., vol. 1, no. 6, pp. 525–531, 2017.
[7] S. Chasani, “Hipertrofi Pristat Benigna,” in Buku Ajar Ilmu Penyakit Dalam, Jakarta: Interna Publishing, 2014, pp. 2139–2148.
[8] J. Lim et al., “Ethnicity is an independent determinant of age-specific PSA level: Findings from a multiethnic Asian setting,” PLoS One, vol. 9, no. 8, 2014, doi: 10.1371/journal.pone.0104917.
[9] A. Prcic, E. Begic, and M. Hiros, “Usefulness of total PSA value in prostate diseases diagnosis,” Acta Inform. Medica, vol. 24, no. 3, pp. 156–161, 2016, doi: 10.5455/aim.2016.24.156-161.
[10] D. S. Park et al., “Correlation between serum prostate specific antigen level and prostate volume in a community-based cohort: Large-scale screening of 35,223 Korean Men,” Urology, vol. 82, no. 6, pp. 1394–1399, 2013, doi: 10.1016/j.urology.2013.07.071.
[11] T. Antony et al., “Correlation of serum prostate specific antigen with clinical, radiological and pathological variables in patients with prostate enlargement,” Int. Surg. J., vol. 6, no. 12, p. 4408, 2019, doi: 10.18203/2349-2902.isj20195403.
[12] M. Bo, M. Ventura, R. Marinello, S. Capello, G. Casetta, and F. Fabris, “Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly.,” Crit. Rev. Oncol. Hematol., vol. 47, no. 3, pp. 207–211, Sep. 2003, doi: 10.1016/s1040-8428(03)00094-5.
[13] Y. L. Chang et al., “Correlation Between Serum Prostate Specific Antigen and Prostate Volume in Taiwanese Men With Biopsy Proven Benign Prostatic Hyperplasia,” J. Urol., vol. 176, no. 1, pp. 196–199, 2006, doi: 10.1016/S0022-5347(06)00568-4.
[14] O. Abdelwahab, H. Sherif, A. Eshazly, and M. Zaazaa, “UroToday International Journal,” Laterality, vol. 33, no. 2, p. 94.3, 2010.
[15] A. Alawad, F. Younis, A. M. Eltoum, and S. A. Abdelgani, “Serum prostate-specific antigen as a predictor of prostate volume in Sudanese patients with benign prostatic hyperplasia,” Int. J. Med., vol. 2, no. 1, pp. 3–6, 2014, doi: 10.14419/ijm.v2i1.2494.
[16] K. Devi, A. Frasiska, A. Agung, and G. Oka, “Usia dan obesitas berhubungan terhadap terjadinya penyakit benign prostatic hyperplasia di RSUP Sanglah Bali periode januari 2014 sampai desember 2014,” E-Jurnal Med., vol. 7, no. 1, pp. 2–4, 2018.
[17] B. Suryawan, “Hubungan Usia Dan Kebiasaan Merokok Terhadap Terjadinya Bph,” J. Med. Malahayati, vol. 3, no. 2, pp. 102–107, 2016.
[18] P. Duvedi, H. Singh, G. K. Bedi, and M. Kaur, “Role of Prostate-Specific Antigen (PSA) in Patients with Benign Prostate Hyperplasia,” J. Clin. Diagnostic Res., pp. 15–17, 2019, doi: 10.7860/jcdr/2019/39748.12814.
[19] S. N. Ayyildiz and A. Ayyildiz, “PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer,” Turk Urol. Derg., vol. 40, no. 2, pp. 82–88, 2014, doi: 10.5152/tud.2014.94547.
[20] P. Widayati, G. Mondrida, S. Setiyowati, A. Ariyanto, V. Y. Susilo, and W. Lestari, “PREPARASI PEREAKSI KIT IMMUNORADIOMETRlCASSAY FREE PROSTATE SPECIFIC ANTIGEN UNTUK DETEKSI KANKER PROSTAT,” J. Kim. Terap. Indones., vol. 15, no. 2, pp. 14–24, 2013, doi: 10.14203/jkti.v15i2.107.
